Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,661 to 1,680 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of All Cause Mortality | 144 of 2,596 148 of 2,602 | -0.1 points -1.4 to 1.1 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer | 12 of 2,596 11 of 2,602 | 0.0 points -0.3 to 0.4 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an Event | 182 of 2,596 190 of 2,602 | -0.3 points -1.7 to 1.1 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Acute Urinary Retention | 20 of 2,596 16 of 2,602 | 0.2 points -0.3 to 0.6 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Pharmacologic Treatment for Lower Urinary Tract Symptoms | 101 of 2,596 87 of 2,602 | 0.5 points -0.5 to 1.6 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Peripheral Arterial Revascularization | 30 of 2,596 33 of 2,602 | -0.1 points -0.7 to 0.5 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Invasive Prostate Surgical Procedures for Benign Prostatic Hyperplasia | 23 of 2,596 12 of 2,602 | 0.4 points -0.0 to 0.9 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Incidence of High-Grade Prostate Cancer | 5 of 2,596 3 of 2,602 | 0.1 points -0.2 to 0.3 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of CV Safety Endpoint: Number and Percentage of Participants With an Event | 269 of 2,596 264 of 2,602 | 0.2 points -1.4 to 1.9 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Biopsy | 16 of 2,596 14 of 2,602 | 0.1 points -0.4 to 0.5 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Venous Thromboembolic Events | 44 of 2,596 30 of 2,602 | 0.5 points -0.1 to 1.2 | 5,198 | NCT03518034 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men |
| TDM Cohort vs Historical Cohort: Number of Participants Categorized Based on Dose Escalation | 173 of 436 852 of 4,758 | 21.8 points 17.2 to 26.6 | 5,194 | NCT04567628 Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes |
| Invasive Strategy (INV) vs Conservative Strategy: Number of Participants That Experienced Death From Any Cause | 145 of 2,588 144 of 2,591 | 0.0 points -1.2 to 1.3 | 5,179 | NCT01471522 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) |
| Invasive Strategy (INV) vs Conservative Strategy: Number of Participants That Experienced Death From Cardiovascular Causes or Myocardial Infarction | 276 of 2,588 314 of 2,591 | -1.5 points -3.2 to 0.3 | 5,179 | NCT01471522 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) |
| Invasive Strategy (INV) vs Conservative Strategy: Number of Participants That Experienced Myocardial Infarction | 210 of 2,588 233 of 2,591 | -0.9 points -2.4 to 0.6 | 5,179 | NCT01471522 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) |
| Invasive Strategy (INV) vs Conservative Strategy: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest | 318 of 2,588 352 of 2,591 | -1.3 points -3.1 to 0.5 | 5,179 | NCT01471522 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) |
| Invasive Strategy (INV) vs Conservative Strategy: deaths from any cause | 145 of 2,588 144 of 2,591 | 0.0 points -1.2 to 1.3 | 5,179 | NCT01471522 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) |
| Invasive Strategy (INV) vs Conservative Strategy: serious adverse events | 318 of 2,588 352 of 2,591 | -1.3 points -3.1 to 0.5 | 5,179 | NCT01471522 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) |
| Opt-in vs Opt-out: Enrollment in GAMEPAD Intervention Study | 39 of 3,909 45 of 1,267 | -2.6 points -3.8 to -1.6 | 5,176 | NCT04536038 Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease |
| Opt-in vs Opt-out: deaths from any cause | 0 of 3,909 1 of 1,267 | -0.1 points -0.4 to 0.0 | 5,176 | NCT04536038 Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=84
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03518034-2e29ac2c",
"title": "AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of All Cause Mortality",
"summary": "144 of 2596 against 148 of 2602; risk difference -0.1 points, 95% interval -1.4 to 1.1; NCT03518034, A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men",
"record": "/library/comparisons/NCT03518034-2e29ac2c",
"nct_id": "NCT03518034",
"kind": "outcome",
"participants": 5198,
"risk_difference": {
"value": -0.0014093698221943757,
"lower": -0.01398992884040385,
"upper": 0.011166498693297038
},
"group_1": "144 of 2,596",
"group_2": "148 of 2,602",
"difference": "-0.1 points",
"interval": "-1.4 to 1.1",
"trial_title": "A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men"
},
{
"id": "NCT03518034-3af6284d",
"title": "AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer",
"summary": "12 of 2596 against 11 of 2602; risk difference 0.0 points, 95% interval -0.3 to 0.4; NCT03518034, A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men",
"record": "/library/comparisons/NCT03518034-3af6284d",
"nct_id": "NCT03518034",
"kind": "outcome",
"participants": 5198,
"risk_difference": {
"value": 0.0003949788535309454,
"lower": -0.0034746852726501055,
"upper": 0.004308268577893304
},
"group_1": "12 of 2,596",
"group_2": "11 of 2,602",
"difference": "0.0 points",
"interval": "-0.3 to 0.4",
"trial_title": "A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=85",
"request_id": "WdaDnQxrWlgCxl4A"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant